MUC5AC mucin release from human airways in vitro: Effects of indomethacin and Bay X1005 | Zendy

Patricia Roger | Zendy; JeanPierre Gascard | Zendy; Jacques Bara | Zendy; Vincent de Montpréville | Zendy; Charles Brink | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

MUC5AC mucin release from human airways in vitro: Effects of indomethacin and Bay X1005

Author(s) -

Patricia Roger,

JeanPierre Gascard,

Jacques Bara,

Vincent de Montpréville,

Charles Brink

Publication year - 2001

Publication title -

mediators of inflammation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.37

H-Index - 97

eISSN - 1466-1861

pISSN - 0962-9351

DOI - 10.1080/09629350124329

Subject(s) - mucin , mucus , cyclooxygenase , lipoxygenase , eicosanoid , in vitro , chemistry , pharmacology , monoclonal antibody , biology , enzyme , biochemistry , immunology , antibody , arachidonic acid , ecology

Increased secretion of mucus is a hallmark of many respiratory diseases and contributes significantly to the airflow limitation experienced by many patients. While the current pharmacological approach to reducing mucus and sputum production in patients is limited, clinical studies have suggested that drugs which inhibit the cyclooxygenase and/or 5-lipoxygenase enzymatic pathways may reduce secretory activity in patients with airway disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research